Teva Steps Up Washington Lobbying Effort

YERUSHALAYIM -

Teva Pharmaceutical Industries invested 40% more on lobbying the U.S. government during 2013 than it had in the previous year, according to Globes.

The Israel-based company spent $3.2 million on lobbying the White House, Congress and federal agencies in January-September 2013, a whopping increase over 2012.

The figures come from its own Lobbying Report, filed under the Lobbying Disclosure Act of 1995.

Teva argued its cause before the House of Representatives, the Senate, the U.S. Food and Drug Administration (FDA), the Patent and Trademark Office, the U.S. Trade Representative, and other relevant agencies.

Among the legislative proposals of interest to Teva are those on drug abuse, drug labeling and electronic labeling proposals, counterfeit drugs, the Safeguarding America’s Pharmaceuticals Act, the Pharmaceutical Quality, Security and Accountability Act, and the Preserve Access to Affordable Generics Act.